Antiarrhythmic properties of the cannabinoid receptor agonist HU-210

Abstract

The cannabinoid (CB1) receptor agonist HU-210 (0.5 mg/kg, i.v.) exhibited a pronounced antiarrhythmic effect in rats with the adrenaline (epinephrine) and aconitine induced arrhythmia models. At the same time, the intracerebrovascular introduction of HU-210 (500 or 5000 ng) did not affect the adrenaline-induced arrhythmia. The CB1 receptor pretreatment (blocking) with the SR 141716 antagonist (3 mg/kg) and the introduction of a ganglion blocker (hexamethonium, 10 mg/kg) did not inhibit the antiarrhythmic effect of HU-210. It is concluded that the antiarrhythmic effect of intravenously injected HU-210 is neither related to the CB 1 receptor activation nor mediated by the autonomous (vegetative) nervous system.

Original language	English
Number of pages	1
Journal	Eksperimental'naya i Klinicheskaya Farmakologiya
Volume	64
Issue number	3
Publication status	Published - 1 Jan 2001

ASJC Scopus subject areas

Toxicology
Pharmacology

Access to Document

Fingerprint Dive into the research topics of 'Antiarrhythmic properties of the cannabinoid receptor agonist HU-210'. Together they form a unique fingerprint.

Cite this

@article{9c43c638a075405cb5a09a95174cb26b,

title = "Antiarrhythmic properties of the cannabinoid receptor agonist HU-210",

abstract = "The cannabinoid (CB1) receptor agonist HU-210 (0.5 mg/kg, i.v.) exhibited a pronounced antiarrhythmic effect in rats with the adrenaline (epinephrine) and aconitine induced arrhythmia models. At the same time, the intracerebrovascular introduction of HU-210 (500 or 5000 ng) did not affect the adrenaline-induced arrhythmia. The CB1 receptor pretreatment (blocking) with the SR 141716 antagonist (3 mg/kg) and the introduction of a ganglion blocker (hexamethonium, 10 mg/kg) did not inhibit the antiarrhythmic effect of HU-210. It is concluded that the antiarrhythmic effect of intravenously injected HU-210 is neither related to the CB 1 receptor activation nor mediated by the autonomous (vegetative) nervous system.",

author = "Maslov, {L. N.} and Lishmanov, {Yu B.} and Maimeskulova, {L. A.} and P. Mechoulam",

year = "2001",

month = jan,

day = "1",

language = "English",

volume = "64",

journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",

issn = "0869-2092",

publisher = "Izdatelstvo Meditsina",

number = "3",

}

TY - JOUR

T1 - Antiarrhythmic properties of the cannabinoid receptor agonist HU-210

AU - Maslov, L. N.

AU - Lishmanov, Yu B.

AU - Maimeskulova, L. A.

AU - Mechoulam, P.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The cannabinoid (CB1) receptor agonist HU-210 (0.5 mg/kg, i.v.) exhibited a pronounced antiarrhythmic effect in rats with the adrenaline (epinephrine) and aconitine induced arrhythmia models. At the same time, the intracerebrovascular introduction of HU-210 (500 or 5000 ng) did not affect the adrenaline-induced arrhythmia. The CB1 receptor pretreatment (blocking) with the SR 141716 antagonist (3 mg/kg) and the introduction of a ganglion blocker (hexamethonium, 10 mg/kg) did not inhibit the antiarrhythmic effect of HU-210. It is concluded that the antiarrhythmic effect of intravenously injected HU-210 is neither related to the CB 1 receptor activation nor mediated by the autonomous (vegetative) nervous system.

AB - The cannabinoid (CB1) receptor agonist HU-210 (0.5 mg/kg, i.v.) exhibited a pronounced antiarrhythmic effect in rats with the adrenaline (epinephrine) and aconitine induced arrhythmia models. At the same time, the intracerebrovascular introduction of HU-210 (500 or 5000 ng) did not affect the adrenaline-induced arrhythmia. The CB1 receptor pretreatment (blocking) with the SR 141716 antagonist (3 mg/kg) and the introduction of a ganglion blocker (hexamethonium, 10 mg/kg) did not inhibit the antiarrhythmic effect of HU-210. It is concluded that the antiarrhythmic effect of intravenously injected HU-210 is neither related to the CB 1 receptor activation nor mediated by the autonomous (vegetative) nervous system.

UR - http://www.scopus.com/inward/record.url?scp=0347715241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347715241&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0347715241

VL - 64

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 3

ER -